Literature DB >> 24331921

Racial differences in risk of spontaneous abortions associated with periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure.

Digna R Velez Edwards1, Katherine E Hartmann2.   

Abstract

PURPOSE: Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most common medications reported in pregnancy. NSAIDs directly impact prostaglandin pathways and have been proposed as potential risk factors for spontaneous abortions (SABs, gestation <20 weeks). SAB risk and drug response across several medications differ by race; therefore, we evaluated whether associations between NSAIDs and SAB risk differ by race.
METHODS: Women were enrolled in the Right from the Start (2004-2010) prospective cohort. Data regarding over-the-counter NSAIDs up to the sixth week of pregnancy were obtained from interviews. Race was self-reported. Cox proportional hazards regression models were used to estimate the association between NSAID exposure and SAB, adjusted for confounders.
RESULTS: Among 2493 pregnancies, 12% were African American and 88% were Caucasian. NSAID exposure was reported by 40% (n = 124) of African Americans and 43% (n = 945) of Caucasians. Race-stratified analyses showed protection from SAB among African Americans (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.73-0.96) but no effect in Caucasians (aHR, 1.01; 95% CI 0.88-1.16).
CONCLUSIONS: Our findings suggest that risk for SAB due to over-the-counter NSAIDs in early pregnancy is modified by race. Further investigation of dose, timing in gestation, and indication may help to further reconcile the relationship between race, NSAIDs, and SAB.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disparity; Miscarriage; Nonsteroidal anti-inflammatory drugs; Pregnancy; Toxicology

Mesh:

Substances:

Year:  2013        PMID: 24331921      PMCID: PMC3946756          DOI: 10.1016/j.annepidem.2013.11.001

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  36 in total

1.  Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group.

Authors:  C Olesen; F H Steffensen; G L Nielsen; L de Jong-van den Berg; J Olsen; H T Sørensen
Journal:  Eur J Clin Pharmacol       Date:  1999-04       Impact factor: 2.953

2.  Method for using complete and incomplete trios to identify genes related to a quantitative trait.

Authors:  Emily O Kistner; Clarice R Weinberg
Journal:  Genet Epidemiol       Date:  2004-07       Impact factor: 2.135

3.  Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia.

Authors:  Henry J Lin; Karen M Lakkides; Temitope O Keku; Srinivasa T Reddy; Andrew D Louie; Irving H Kau; Haiyan Zhou; Jason S Y Gim; Hoang L Ma; Carl F Matthies; Aihua Dai; Hsiao-Fen Huang; Alicia M Materi; Jesse H Lin; Harold D Frankl; Eric R Lee; Steven I Hardy; Harvey R Herschman; Brian E Henderson; Laurence N Kolonel; Loïc Le Marchand; R Michael Garavito; Robert S Sandler; Robert W Haile; William L Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

4.  The impact of embryonic development and endometrial maturity on the timing of implantation.

Authors:  P A Bergh; D Navot
Journal:  Fertil Steril       Date:  1992-09       Impact factor: 7.329

5.  Prostaglandin and cytokine release by trophoblastic villi.

Authors:  R W Kelly; G G Carr; C L Elliott; M Tulppala; H O Critchley
Journal:  Hum Reprod       Date:  1995-12       Impact factor: 6.918

6.  Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study.

Authors:  De-Kun Li; Liyan Liu; Roxana Odouli
Journal:  BMJ       Date:  2003-08-16

7.  Prostaglandin E2 enhances human endometrial stromal cell differentiation.

Authors:  G R Frank; A K Brar; M I Cedars; S Handwerger
Journal:  Endocrinology       Date:  1994-01       Impact factor: 4.736

8.  Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women.

Authors:  Gary C Curhan; Andrea J Bullock; Susan E Hankinson; Walter C Willett; Frank E Speizer; Meir J Stampfer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002-12       Impact factor: 2.890

9.  The use of transvaginal color flow imaging after in vitro fertilization to identify optimum uterine conditions before embryo transfer.

Authors:  C V Steer; S Campbell; S L Tan; T Crayford; C Mills; B A Mason; W P Collins
Journal:  Fertil Steril       Date:  1992-02       Impact factor: 7.329

10.  Activation of maternal killer cells in the pregnant uterus with chronic indomethacin therapy, IL-2 therapy, or a combination therapy is associated with embryonic demise.

Authors:  P K Lala; J M Scodras; C H Graham; J J Lysiak; R S Parhar
Journal:  Cell Immunol       Date:  1990-05       Impact factor: 4.868

View more
  4 in total

1.  Validation of maternal recall of early pregnancy medication exposure using prospective diary data.

Authors:  Alexandra C Sundermann; Katherine E Hartmann; Sarah H Jones; Eric S Torstenson; Digna R Velez Edwards
Journal:  Ann Epidemiol       Date:  2016-12-09       Impact factor: 3.797

2.  MTHFR gene polymorphism and homocysteine levels in spontaneous abortion of pregnant women.

Authors:  Linjing Zhang; Hainei Fu; Tao Wei
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  [Prevalence of the use of nonsteroidal anti-inflammatory drugs in pregnant women in Lubumbashi (Democratic Republic of Congo)].

Authors:  Arsène Tshikongo Kabamba; Laurent Kwete Shamashanga; Jean-Jacques Mulubwa Mwaba; Christian Busambwa Kasongo; Albert Otshudi Longanga; Zet Kalala Lukumwena
Journal:  Pan Afr Med J       Date:  2014-06-11

4.  Nonsteroidal Anti-inflammatory Drug Interaction with Prostacyclin Synthase Protects from Miscarriage.

Authors:  Digna R Velez Edwards; Todd L Edwards; Michael J Bray; Eric Torstenson; Sarah Jones; Martha J Shrubsole; Harvey J Muff; Katherine E Hartmann
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.